AGC Biologics
AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO) headquartered in Bothell, Washington, United States. The company specializes in the development and manufacturing of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells.
As the biotech arm of AGC Inc. (formerly Asahi Glass Co., Ltd.), a global materials and chemicals giant, AGC Biologics was formed through the integration of several specialized entities, including CMC Biologics, Biomeva, and Molecular Medicine. The company serves pharmaceutical and biotechnology firms worldwide, providing a "bench-to-market" partnership that spans early-phase development, clinical trials, and full-scale commercial production.
Continue…Core Capabilities and Services
AGC Biologics operates as a "one-stop-shop" for biopharmaceutical manufacturing, offering distinct service lines tailored to specific biologic modalities.
1. Mammalian Manufacturing
The company's mammalian division focuses on the production of complex proteins, including monoclonal antibodies (mAbs), fusion proteins, and enzymes.
* Scale and Flexibility: They utilize both single-use technologies and large-scale stainless steel bioreactors. Capacities range from small-scale development runs to 20,000L commercial production lines.
* Perfusion Technology: AGC Biologics is recognized for its expertise in perfusion processes, a continuous manufacturing technique that allows for higher productivity and product stability compared to traditional fed-batch methods.
* Cell Line Development: The firm offers custom cell line development services to create high-yield clones suitable for GMP manufacturing.
2. Microbial Manufacturing
AGC Biologics is one of the few global CDMOs with deep expertise in microbial fermentation, using bacteria (E. coli) and yeast (Pichia pastoris) to produce therapeutic proteins.
* Complex Expression: This service is essential for producing antibody fragments, growth factors, and vaccines that are often difficult to express in mammalian systems.
* Refolding Capabilities: They possess specialized capabilities in inclusion body processing and protein refolding, a critical step in recovering active proteins from microbial fermentation.
3. Cell and Gene Therapy (Advanced Therapies)
The company has aggressively expanded its capabilities in the Cell and Gene Therapy (CGT) sector, operating dedicated Centers of Excellence in Milan, Italy, and Longmont, Colorado.
- Viral Vectors: They manufacture the critical delivery vehicles used in gene therapies, specifically Adeno-Associated Viral (AAV) vectors, Lentiviral (LVV) vectors, and Retroviral (RVV) vectors.
- Cell Therapy: Services include the development and manufacturing of autologous (patient-specific) and allogeneic (off-the-shelf) cell therapies. This involves the genetic modification of cells (e.g., CAR-T cells) for oncology and rare disease treatments.
- Plasmid DNA (pDNA): AGC Biologics manufactures pDNA, which serves as a critical starting material for the production of viral vectors and mRNA vaccines.
Proprietary Technology Platforms
AGC Biologics distinguishes itself through proprietary technologies designed to accelerate development timelines and improve yields.
CHEF1 Expression System
The CHEF1 Expression System is the company's proprietary mammalian cell line development platform.
* Speed: It allows for the rapid generation of high-expressing Chinese Hamster Ovary (CHO) cell lines.
* Stability: The system uses a specialized vector that ensures long-term genetic stability of the cell line, which is crucial for consistent commercial manufacturing.
* Regulatory Track Record: The platform has been used in the production of multiple commercially approved drugs on the market today.
AGCellerate Program
AGCellerate is a program designed to speed up the "IND-enabling" phase (Investigational New Drug). It offers fixed timelines and costs to deliver GMP-grade material for clinical trials, specifically targeting monoclonal antibodies and lentiviral vectors.
Global Operational Network
AGC Biologics operates a network of cGMP-compliant facilities across three continents, allowing them to offer redundant supply chains and local regulatory expertise.
- North America:
- Bothell, Washington: Headquarters and primary site for mammalian and microbial manufacturing.
- Boulder & Longmont, Colorado: Specialized large-scale mammalian production and cell/gene therapy hubs.
- Europe:
- Copenhagen, Denmark: A major hub for mammalian development and manufacturing.
- Heidelberg, Germany: The center of excellence for microbial fermentation.
- Milan, Italy: A world-renowned facility for cell and gene therapy (formerly Molecular Medicine).
- Asia:
- Chiba & Yokohama, Japan: Facilities serving the Asian market with mammalian manufacturing capabilities.
Summary
AGC Biologics functions as the manufacturing engine behind many of the world's most innovative drugs. By handling the complex, highly regulated processes of biomanufacturing?from growing cells in giant tanks to purifying microscopic viral vectors?they allow drug developers to focus on discovery and clinical research. Their broad portfolio, covering everything from standard antibodies to cutting-edge gene editing tools, positions them as a critical infrastructure partner in the modern life sciences ecosystem.
